Table 1.
Baseline characteristics of included patients
| Total (N = 232) | Vitalograph COPD-6 (N = 92) | AioCare (N = 140) | P-value | |
|---|---|---|---|---|
| Age (years) | 66 [59–71] | 66 [59–71] | 65 [59–71] | 0.907 |
| Male | 158 (68.1) | 60 (65.2) | 98 (70.0) | 0.445 |
| BMI (kg/m2) | 27.8 [25.4–30.5] | 27.7 [25.4–30.3] | 27.8 [25.3–31.1] | 0.614 |
| Hypertension | 106 (45.7) | 42 (45.7) | 64 (45.7) | 0.993 |
| Diabetes mellitus | 21 (9.1) | 8 (8.7) | 13 (9.3) | 0.878 |
| Hypercholesterolemia | 55 (23.7) | 17 (18.5) | 38 (27.1) | 0.129 |
| Coronary artery disease | 30 (12.9) | 13 (14.1) | 17 (12.1) | 0.659 |
| Heart failure | 36 (15.7) n = 229 | 12 (13.0) | 24 (17.1) n = 137 | 0.362 |
| Thromboembolic events | 26 (11.2) | 10 (10.9) | 16 (11.4) | 0.895 |
| COPD (previously diagnosed) | 14 (6.0) | 7 (7.6) | 7 (5.0) | 0.414 |
| Smoking—currently or previously | 88 (39.1) n = 225 | 31 (33.7) n = 88 | 57 (40.7) n = 137 | 0.339 |
| CHA2DS2-VASc score | 2 [1–3] | 2 [1–3] | 2 [1–3] | 0.974 |
| AF characteristics | ||||
| AF type | Paroxysmal—146 (63.5) | Paroxysmal—60 (65.9) | Paroxysmal—86 (61.9) | 0.531 |
| Persistent—84 (36.5) n = 230 | Persistent—31 (34.1) n = 91 | Persistent—53 (37.9) n = 139 | ||
| EHRA classification | I–12 (5.2) | I–6 (6.5) | I–6 (4.3) | 0.750 |
| II–167 (72.0) | II–65 (70.7) | II–102 (72.9) | ||
| III–53 (22.8) | III–21 (22.8) | III–32 (22.9) | ||
| Self-reported dyspnoea | 78 (33.6) | 31 (33.7) | 47 (33.6) | 0.938 |
| Cardiovascular medication | ||||
| Beta-blockers | 104 (44.8) | 45 (48.9) | 59 (42.1) | 0.310 |
| Digitalis | 18 (7.8) | 9 (9.8) | 9 (6.4) | 0.350 |
| Antiarrhythmic drugsa | 117 (50.4) | 45 (48.9) | 72 (51.4) | 0.708 |
| NCCB | 13 (5.6) | 5 (5.4) | 8 (5.7) | 0.928 |
| RAS inhibitors | 92 (39.7) | 39 (42.4) | 53 (37.9) | 0.490 |
| MRA | 1 (0.4) | 0 | 1 (0.7) | 1.000 |
| Diuretics | 39 (16.8) | 15 (16.3) | 24 (17.1) | 0.867 |
| DCCB | 20 (8.6) | 8 (8.7) | 12 (8.6) | 0.974 |
| Statins | 85 (36.6) | 34 (37.0) | 51 (36.4) | 0.935 |
| Vasodilators | 12 (5.2) | 3 (3.3) | 9 (6.4) | 0.287 |
| VKA | 3 (1.3) | 0 | 3 (2.1) | 0.279 |
| NOAC | 221 (96.5) n = 228 | 88 (96.7) n = 91 | 133 (96.4) n = 137 | 1.000 |
Number provided in italics indicates the total number of patients available for that variable. Data is presented as no. (%) or median [IQR].
Abbreviations: AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; DCCB, dihydropyridine calcium channel blocker; EHRA, European Heart Rhythm Association; MRA, mineralocorticoid receptor antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; NCCB, non dihydropyridine calcium channel blocker; RAS, renin–angiotensin system; VKA, vitamin K antagonist.
a
Either flecainide, amiodarone, or sotalol.